Aggressive policies that target the use and promotion of off-label use are needed to prevent the use of drugs for non-approved indications with little benefit or with harmful outcomes. It should be ...
When you shop through retailer links on our site, we may earn affiliate commissions. 100% of the fees we collect are used to support our nonprofit mission. Learn more. Nervous about giving a big ...
The Food and Drug Administration (FDA) authorizes the marketing of drugs only for uses that the manufacturer has demonstrated to be safe and effective. However, the FDA does not regulate medical ...
Dabigatran has been readily integrated into clinical practice in the United States, primarily for treatment of atrial fibrillation (A-fib) but increasingly for off-label indications as well, according ...
The National Comprehensive Cancer Network ® (NCCN ®) announces the latest in its series of Policy Summits, Issues in Off-Label Use and the Applications of Compendia. This NCCN Oncology Policy Summit ...
In a recent national survey, a substantial minority of physicians erroneously believed that certain off-label uses of prescription drugs were approved by the Food and Drug Administration. This ...
A new study finds that off-label drug use is associated with higher rates of adverse drug events in adults. Off-label use of prescription drugs is known to be associated with adverse drug events (ADEs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback